<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Ann Med</journal-id><journal-id journal-id-type="iso-abbrev">Ann Med</journal-id><journal-title-group><journal-title>Annals of Medicine</journal-title></journal-title-group><issn pub-type="ppub">0785-3890</issn><issn pub-type="epub">1365-2060</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38109924</article-id><article-id pub-id-type="pmc">PMC10732206</article-id>
<article-id pub-id-type="doi">10.1080/07853890.2023.2280991</article-id><article-id pub-id-type="publisher-id">2280991</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version><article-categories><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Dermatology</subject></subj-group></article-categories><title-group><article-title>Study of cytokine-induced immunity in bullous pemphigoid: recent developments</article-title><alt-title alt-title-type="left-running-head">R. Huang et al.</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Ruiting</given-names></name><xref rid="AF0001" ref-type="aff"/><xref rid="AUFN1" ref-type="author-notes">&#x02021;</xref></contrib><contrib contrib-type="author"><name><surname>Hu</surname><given-names>Lingyu</given-names></name><xref rid="AF0001" ref-type="aff"/><xref rid="AUFN1" ref-type="author-notes">&#x02021;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8207-2838</contrib-id><name><surname>Jiang</surname><given-names>Fuqiong</given-names></name><xref rid="AF0001" ref-type="aff"/><xref rid="AN0001" ref-type="corresp"/></contrib><aff id="AF0001"><institution>Department of Dermatology, The Second Affiliated Hospital of Kunming Medical University</institution>, <city>Kunming</city>, <country>China</country></aff></contrib-group><author-notes><fn id="AUFN1"><label>&#x02021;</label><p>Both authors contributed equally to this work.</p></fn><corresp id="AN0001">CONTACT Fuqiong Jiang <email xlink:href="mailto:mmwjl528jfq@aliyun.com">mmwjl528jfq@aliyun.com</email>
<institution>Department of Dermatology, The Second Affiliated Hospital of Kunming Medical University</institution>, <addr-line>No. 374 Dianmian Road, Wuhua District</addr-line>, <city>Kunming</city>
<postal-code>650101</postal-code>, <state>Yunnan Province</state>, <country>China</country></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>18</day><month>12</month><year>2023</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2023</year></pub-date><pub-date pub-type="pmc-release"><day>18</day><month>12</month><year>2023</year></pub-date><volume>55</volume><issue>2</issue><elocation-id>2280991</elocation-id><pub-history><event event-type="received"><date><day>16</day><month>5</month><year>2023</year></date></event><event event-type="revised"><date><day>20</day><month>7</month><year>2023</year></date></event><event event-type="accepted"><date><day>4</day><month>11</month><year>2023</year></date></event><event event-type="tagger"><event-desc>KnowledgeWorks Global Ltd.</event-desc><date><day>18</day><month>12</month><year>2023</year></date></event><event event-type="build-issue-online"><event-desc>published online in a building issue</event-desc><date><day>18</day><month>12</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#x000a9; 2023 The Author(s). Published by Informa UK Limited, trading as Taylor &#x00026; Francis Group</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="IANN_55_2280991.pdf"/><abstract><title>Abstract</title><p>Bullous pemphigoid (BP) is an organ-specific disease. Its pathogenesis has not been clearly studied yet; However, studies in recent years have shown that its pathogenesis is related to T helper cells. The pathogenesis of BP is mainly related to Th2 and Th17-related cytokines. IL-4, IL-5 and IL-13 cause eosinophil recruitment, promote antibody production, trigger pruritus and promote blister formation and other symptoms. IL-17 and IL-23 promote the production of matrix metalloproteinase-9 (MMP-9) by related cells, which causes dermo-epidermal junction (DEJ) separation to form bullae and blisters, and can persist in BP inflammation. The serum concentrations of IL-17 and IL-23 are related to the prognosis of BP. In this paper, we focus on the role of related cytokines in the pathogenesis of bullous pemphigoid and the relationship between the related cytokine populations secreted by three major T helper cells&#x02014;helper T lymphocytes 1 (Th1), Th2, and Th17. A better understanding of the biological and immunological functions of cytokines associated with BP patients will provide opportunities for therapeutic targets in BP.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>Bullous pemphigoid</kwd><kwd>cytokines</kwd><kwd>interferon-&#x003b3;</kwd><kwd>interleukin-4</kwd><kwd>Th1 cells</kwd><kwd>Th2 cells</kwd><kwd>Th17 cells</kwd></kwd-group><support-group><funding-group><award-group><funding-source>
<institution-wrap><institution>Postgraduate Innovation Fund of Kunming Medical University 2022</institution></institution-wrap>
</funding-source><award-id>2022S283</award-id></award-group><funding-statement>This work is supported by the Postgraduate Innovation Fund of Kunming Medical University 2022 (No. 2022S283), Science and Technology Fund of Yunnan Province: 202301AY070001-248, and Clinical Research Fund of the Second Affiliated Hospital of Kunming Medical University: ynllT2022006.</funding-statement></funding-group></support-group><counts><fig-count count="1"/><table-count count="0"/><page-count count="6"/><word-count count="4175"/></counts></article-meta></front><body><sec disp-level="1" id="S0001"><label>1.</label><title>Background</title><p>Bullous pemphigoid (BP) is an autoimmune subepidermal bullous disease caused by the production of antibodies targeting cell adhesion molecules. These antibodies can disrupt the connection between the epidermis and the basement membrane, resulting in the formation of vesicles and bullae. In recent years, researchers have categorized the categories of inflammatory response according to the distinct T helper (Th) cells differentiated by stimulation of primitive T cells and the secreted cytokine populations [<xref rid="CIT0001" ref-type="bibr">1</xref>]. Th1 cells and their secreted cellular inflammatory factors are primarily responsible for the type 1 inflammatory response. The type 2 inflammatory response is characterized by an immune inflammatory response produced mainly by Th2 cells, type 2 innate lymphoid cells, and their secreted cytokine populations [<xref rid="CIT0002" ref-type="bibr">2</xref>]. Th17 cells and their secreted cytosolic inflammatory factors are primarily responsible for the type 3 inflammatory response [<xref rid="CIT0003" ref-type="bibr">3</xref>]. Numerous studies have demonstrated that Th cells play a significant role in the pathogenesis of BP, and an increasing number of researchers are investigating the cytokines associated with BP pathogenesis [<xref rid="CIT0004" ref-type="bibr">4</xref>,<xref rid="CIT0005" ref-type="bibr">5</xref>]. To explore the relationship between different classes of cytokines and BP, we reviewed the literature on three main classes of T lymphocyte-associated cytokines involved in these three types of inflammatory responses.</p></sec><sec disp-level="1" id="S0002"><label>2.</label><title>Th1-like cytokines associated with BP</title><p>Th1 cells and the cytosolic inflammatory factors they secrete are mainly responsible for the type 1 inflammatory response. Th1 cells primarily secrete interleukin-2 (IL-2), interleukin-12 (IL-12), interferon-&#x003b3; (IFN-&#x003b3;) and tumour necrosis factor &#x003b2; (TNF-&#x003b2;), and mediate immune responses related to cytotoxicity and local inflammation. They also participate in cellular immunity and the progression of delayed hypersensitivity associated with diseases such as multiple sclerosis, autoimmune type 1 diabetes and rheumatoid arthritis. They also play an important role in the prevention of infection by intracellular pathogens (viruses, bacteria and parasites) [<xref rid="CIT0006" ref-type="bibr">6</xref>].</p><p>The BP180 non-collagenous 16A (BP180NC16A) domain is the major immunodominant region, and T cells from patients with BP exhibit specific proliferative responses to recombinant forms of the BP180NC16A domain. They proliferate <italic toggle="yes">in vitro</italic> with specific BP180-reactive CD4<sup>+</sup> T cells that are cloned with CD4<sup>+</sup> T cells and produce Th1- and Th2-associated cytokines [<xref rid="CIT0007" ref-type="bibr">7</xref>]. Using reverse PCR and specific cytokine primers, it has been observed that BP180-specific T cell lines produce IL-2, IL-4, IL-5, IL-6 and IFN-&#x003b3; at the mRNA level as well as at the protein level [<xref rid="CIT0008" ref-type="bibr">8</xref>]. These studies indicate the involvement of self-reactive Th1 and Th2 cells in the pathogenesis of BP.</p><p>The characteristic chemokine receptors of Th1 cells are CXCR3 and CCR5 [<xref rid="CIT0009" ref-type="bibr">9</xref>]. The ligands of CXCR3 are CXCL9, CXCL10 and CXCL11, and the ligands of CCR5 are CCL2, CCL3, CCL4 and CCL5, which primarily contribute to the recruitment of Th1 cells. Studies have shown that patients with BP have significantly elevated serum CXCL10 levels [<xref rid="CIT0010" ref-type="bibr">10</xref>], and it has also been reported that patients with BP have significantly elevated serum CCL2 and CXCL10 levels. This correlates positively with disease severity [<xref rid="CIT0011" ref-type="bibr">11</xref>]. However, the source of these chemokines is unknown.</p><p>In contrast, BP180 could produce Th1 cell responses in healthy controls, and peripheral T cells that reacted with BP180 were detected in healthy donors using an enzyme-linked immunospot assay. These T cells predominantly belonged to the Th1 subpopulation, which produces IFN-&#x003b3; [<xref rid="CIT0012" ref-type="bibr">12</xref>]. Therefore, the role of Th1-related cytokines in the pathogenesis of BP is controversial.</p></sec><sec disp-level="1" id="S0003"><label>3.</label><title>Th2-like cytokines associated with BP</title><p>The type 2 inflammatory response is mostly linked to Th2 cells, type 2 innate lymphoid cells and the number of cytokines that they release. The primary function of type 2 inflammatory cytokines is to stimulate the proliferation of B cells and to produce antibodies that are associated with humoral immunity, and they also play an important role in allergic and atopic diseases [<xref rid="CIT0013" ref-type="bibr">13</xref>,<xref rid="CIT0014" ref-type="bibr">14</xref>]. They are also involved in barrier immunity on mucosal surfaces and in protection against parasitic infections [<xref rid="CIT0015" ref-type="bibr">15</xref>].</p><p>Although a mixed spectrum of Th1 and Th2 was initially thought to be the main mediator of the immune response to BP, as studies progressed, it was discovered that there was a significant infiltration of inflammatory cells, primarily eosinophils and CD4<sup>+</sup> T cells, in the upper dermis of patients with BP, in addition to the presence of large numbers of eosinophils and their activated cytokines and chemokines in the serum [<xref rid="CIT0016" ref-type="bibr">16</xref>,<xref rid="CIT0017" ref-type="bibr">17</xref>]. Further research revealed that Th2-related cytokines and chemokines, such as IL-4, IL-5, CCL-13, CCL-18 and the eosinophil chemokine (eotaxin), were highly expressed in BP lesions [<xref rid="CIT0018" ref-type="bibr">18</xref>]. The titer of CCL-18 in the serum of patients with BP was 1.84 times higher than that of healthy controls, and its titer was linearly correlated with the patients&#x02019; clinical scores. The titer of CCL-18 in the patients&#x02019; blister fluid was even higher, at five times the titer of their own serum [<xref rid="CIT0019" ref-type="bibr">19</xref>], indicating that the pathogenesis in patients with BP was primarily mediated by Th2 inflammation. In addition, clones of T cell lines responsive to specific peptides in the BP180 antigen have been identified in patients with BP, and these BP180-specific Th cells characteristically secrete Th2 cytokines, which also contribute to the recruitment of eosinophils.</p><p>In conclusion, this advantage of Th2 cytokines is indicative of BP. Specifically, the Th2-like cytokines associated with BP consist primarily of IL-4, IL-5, IL-10, IL-13 and IL-15.</p><p>IL-4 is an essential regulator of Th2 cell differentiation and a crucial factor in the B cell isotype switch. It is primarily linked to the production and activation of B cells, which enables them to produce autoantibodies [<xref rid="CIT0020" ref-type="bibr">20</xref>]. Experiments revealed that stimulation of peripheral blood mononuclear cells (PBMCs) with recombinant BP180NC16A domain significantly increased IL-4 secretion [<xref rid="CIT0021" ref-type="bibr">21</xref>]. In addition, 22 overlapping peptides spanning the entire sequence of the BP180 NC16A domain were synthesized in experiments, and the sensitivity of Th2 cells from patients with BP to these peptides was investigated using ELISPOT. It was demonstrated that two major epitope peptides, P2 (492-506 aa: VRKLKARVDELERIR) and P5 (501-515 aa: ELERIRRSIL PYGDS), stimulated CD4<sup>+</sup> T cell proliferation by inducing the production of IL-4 cytokines and the activation of B cell autoantibody secretion [<xref rid="CIT0022" ref-type="bibr">22</xref>].</p><p>IL-5 is primarily associated with eosinophil recruitment and activation, and it has been demonstrated that IL-4 and IL-5 enable eosinophils in patients with BP to respond to blister fluid at lower concentrations [<xref rid="CIT0023" ref-type="bibr">23</xref>,<xref rid="CIT0024" ref-type="bibr">24</xref>]. At the same time, IL-5 can also induce the separation of the dermo-epidermal junction (DEJ) through matrix metalloproteinase-9 (MMP-9) production. In the mouse model, MMP-9 can influence downstream neutrophil elastase activity by deactivating &#x003b1;1-protease inhibitor, resulting in the degradation of BP180 and the eventual separation of DEJ [<xref rid="CIT0025" ref-type="bibr">25</xref>]. In addition, IL-5 levels correlate with BP disease activity. A meta-analysis revealed that the IL-5 level in serum and vesicles was significantly elevated in patients with BP [<xref rid="CIT0026" ref-type="bibr">26</xref>].</p><p>The frequency of regulatory B cells producing the anti-inflammatory factor IL-10 was not significantly different when stimulating PBMC in Kabuto&#x02019;s study, after the number of PBMC in the healthy control and BP groups were controlled [<xref rid="CIT0027" ref-type="bibr">27</xref>]. Other studies have demonstrated that the IL-10 level in the serum of patients with BP before treatment was comparable to that of healthy controls, but increased in patients with BP after treatment [<xref rid="CIT0028" ref-type="bibr">28</xref>]. The increase in the number of cells producing IL-10 as a result of treatment with corticosteroids may account for the elevated IL-10 serum levels. In contrast, patients with severe clinical manifestations and treatment resistance were frequently associated with low levels of IL-10, which regulates T-cell secretion [<xref rid="CIT0029" ref-type="bibr">29</xref>]. Alternatively, elevated levels of IL-10 were only detected in the serum of patients who achieved complete remission when treated with rituximab. In conclusion, IL-10 may be relatively deficient in the serum of patients with BP and cannot assure adequate immunoregulation in states of enhanced immune response; however, the therapeutic application of IL-10 is associated with improvement in the treatment of BP [<xref rid="CIT0030" ref-type="bibr">30</xref>,<xref rid="CIT0031" ref-type="bibr">31</xref>].</p><p>The IL-13 level in the serum of patients with BP was significantly higher than that of the healthy subject group. Wang et&#x000a0;al. found that IL-13 was associated with BP in terms of allele, genotype, haplotype and serum cytokine concentration [<xref rid="CIT0032" ref-type="bibr">32</xref>]. The up-regulated expression of IL-13 occurs primarily through the induction of endothelial vascular cell adhesion molecule-1 (VCAM-1) to bind to the integrin &#x003b1;4&#x003b2;1 receptor on relevant inflammatory cells, resulting in the migration of cells such as eosinophils, macrophages and T cells [<xref rid="CIT0033" ref-type="bibr">33</xref>]. Serum immunoglobulin E (IgE) is elevated in patients with BP. It has been reported that 22&#x02013;100% of patients with BP have elevated serum IgE levels and IgE titers are correlated with disease activity [<xref rid="CIT0034" ref-type="bibr">34</xref>,<xref rid="CIT0035" ref-type="bibr">35</xref>]. IL-13 can facilitate the differentiation of B cells into mature plasma cells and mediate the plasma cells secretion of IgE antibodies [<xref rid="CIT0032" ref-type="bibr">32</xref>, <xref rid="CIT0036" ref-type="bibr">36</xref>]. This indicates that IL-13 is related to the pathogenesis of BP.</p><p>In the blister fluid of patients with BP, a significantly positive correlation between IL-15 and IL-5 concentrations has been found, as well as a positive correlation between IL-15 and lesion severity [<xref rid="CIT0037" ref-type="bibr">37</xref>]. As an upstream cytokine, IL-15 can bind to the IL-15 receptor on helper T cells to activate the signal transducer and activator of transcription 5 (STAT5) and produce IL-5, IL-13 and eosinophil chemotactic protein (eotaxin) [<xref rid="CIT0038" ref-type="bibr">38</xref>,<xref rid="CIT0039" ref-type="bibr">39</xref>]. In fact, the IL-15 gene is the most frequently expressed cytokine in B cells specific for BP180. Therefore, IL-15 may be a cytokine that plays a crucial role in the eosinophilia found in patients with BP.</p><p>In conclusion, the activation of Th2 cells and the production of related cytokines can further stimulate the proliferation of B cells and the production of autoantibodies, promoting the transition of immunoglobulins to IgG4 and IgE subtypes, mast cell degranulation and eosinophil activation. In turn, eosinophils promote the differentiation of T cells into Th2 cells, thereby generating positive feedback that maintains the hyperinflammatory state in patients with BP.</p></sec><sec disp-level="1" id="S0004"><label>4.</label><title>Th17-like cytokines associated with BP</title><p>Th17 cells and their secreted IL-17, IL-22 and IL-23 cellular inflammatory factors are primarily involved in type 3 inflammatory response and can prevent infections through the recruitment of neutrophils and macrophages [<xref rid="CIT0040" ref-type="bibr">40</xref>]. They are associated with anti-extracellular bacterial and antifungal infections, as well as playing a role in psoriasis and inflammatory bowel disease, and have been studied in patients with BP [<xref rid="CIT0041" ref-type="bibr">41</xref>].</p><p>Immunohistochemical staining demonstrated the presence of Th17 cells in the lesions of patients with BP. Under certain conditions, myeloid dendritic cells (mDC) can produce IL-1&#x003b2; and IL-23, which can mediate the maturation of Th17 from naive cluster differentiated antigen 161 (CD161)-positive T cells and induce Th17 to produce a series of cytokines represented by IL-17 [<xref rid="CIT0042" ref-type="bibr">42</xref>]. Studies have been conducted to treat wild-type mice injected with anti-BP180 IgG with anti-IL-17A and an isotype-control antibody. They demonstrated that mice treated with anti-IL-17A antibodies had significantly fewer lesions than mice treated with a control antibody [<xref rid="CIT0043" ref-type="bibr">43</xref>]. According to a number of studies, IL-17 and IL-23 can stimulate monocytes and neutrophils to produce MMP-9 [<xref rid="CIT0044" ref-type="bibr">44</xref>,<xref rid="CIT0045" ref-type="bibr">45</xref>]. The protease can mediate the dermo-epidermal division. The effect of IL-17 on MMP-9 secretion was prominent, despite the fact that IL-17 levels in the serum of patients with BP did not differ from those of the healthy group and were unrelated to disease severity. In addition, the serum levels of IL-17 and IL-23 remained elevated in patients with BP at risk for relapse. Meanwhile, both IL-17 and IL-23 independently induce the formation of extracellular traps (ETs) in patients with BP relapse, particularly neutrophil ETs, which are surrounded by chromatin DNA filaments and granule proteins as they are released by neutrophils to trap microbiomes. In patients with BP, they can be precisely located at the edge of the dermo-epidermal separation. <italic toggle="yes">In vitro</italic> experiments have also demonstrated that the degradation of DNA filaments inhibits the division of DEJ [<xref rid="CIT0046" ref-type="bibr">46</xref>]. In conclusion, IL-17 is associated with vesicle formation in patients with BP.</p><p>In addition, the serum concentration of IL-17 can influence the therapeutic effects of glucocorticoids. Steroid resistance is associated with increased expression of glucocorticoid receptor &#x003b2; (GR-&#x003b2;) [<xref rid="CIT0047" ref-type="bibr">47</xref>,<xref rid="CIT0048" ref-type="bibr">48</xref>], and IL-17 and IL-23 can significantly upregulate the expression of GR-&#x003b2; mRNA, thereby affecting the response to BP treatment [<xref rid="CIT0049" ref-type="bibr">49</xref>].</p></sec><sec sec-type="conclusions" disp-level="1" id="S0005"><label>5.</label><title>Conclusions</title><p>In conclusion, the pathogenesis of BP is primarily associated with Th2 and Th17-related cytokines, which cause eosinophil recruitment by IL-4, IL-5 and IL-13, promote antibody production, trigger pruritus, and promote vesicle formation and other symptoms, while IL-17 is also associated with the formation of bullae and vesicles that can perpetuate inflammation in BP. The serum concentration is associated with disease progression.</p><p>Some biologics, such as dupilumab, that target the above cytokines can inhibit the IL-4/13 signal pathway in a targeted manner and have been used clinically to induce therapeutic effects in a variety of diseases with type 2 inflammatory response. Currently, a multicentre, randomized, double-blind, parallel-group, placebo-controlled clinical trial (NCT04206553) is investigating dupilumab efficacy in BP. The efficacy is adequate based on the number of individual cases reported [<xref rid="CIT0050" ref-type="bibr">50</xref>]. Of course, some failures were also reported, such as the phase II clinical trial of an IL-5-targeting drug for BP, which ultimately ended in failure [<xref rid="CIT0051" ref-type="bibr">51</xref>].</p><p>In conclusion, additional research is required to ascertain how a large and complex network of cytokines affects the pathogenesis of BP (<xref rid="F0001" ref-type="fig">Figure 1</xref>), as well as the use of immunoregulatory and clinical biological preparations.</p><fig position="float" id="F0001"><label>Figure 1.</label><caption><p>A network of cytokines affects the pathogenesis of BP. The pathogenesis of BP is primarily associated with cytokines related to Th2 and Th17. IL-4, IL-5 and IL-13 cause the recruitment of eosinophils, stimulate the production of antibodies, induce pruritus, promote blister formation and cause other symptoms. IL-17 and IL-23 stimulate the production of matrix metalloproteinase-9 (MMP-9) by related cells, which leads to dermo-epidermal junction (DEJ) separation and the formation of bullae and blisters and can persist in BP inflammation. The serum concentrations of IL-17 and IL-23 are associated with the prognosis of BP.</p></caption><graphic xlink:href="IANN_A_2280991_F0001_C" content-type="color" position="float"/></fig></sec></body><back><ack><title>Acknowledgements</title><p>We would like to acknowledge the hard and dedicated work of all the staff that implemented the intervention and evaluation components of the study.</p></ack><sec disp-level="1" id="S0006"><title>Author contributions</title><p>Conception and design of the research: Ruiting Huang and Fuqiong Jiang. Acquisition of data: Ruiting Huang, Lingyu Hu and Fuqiong Jiang. Analysis and interpretation of the data: Ruiting Huang. Statistical analysis: Ruiting Huang, Lingyu Hu and Fuqiong Jiang. Obtaining financing: Ruiting Huang and Fuqiong Jiang. Writing of the manuscript: Ruiting Huang and Fuqiong Jiang. Critical revision of the manuscript for intellectual content: Fuqiong Jiang, Ruiting Huang and Lingyu Hu. All authors read and approved the final draft.</p></sec><sec sec-type="COI-statement" disp-level="1" id="S0007"><title>Disclosure statement</title><p>The authors declare that they have no competing interests.</p></sec><sec sec-type="data-availability" disp-level="1" id="S0008"><title>Data availability statement</title><p>The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Annunziato</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Romagnani</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Romagnani</surname>
<given-names>S.</given-names></string-name></person-group>
<article-title>The 3 major types of innate and adaptive cell-mediated effector immunity</article-title>. <source>J Allergy Clin Immunol</source>. <year>2015</year>;<volume>135</volume>(<issue>3</issue>):<fpage>1</fpage>&#x02013;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jaci.2014.11.001</pub-id>.</mixed-citation></ref><ref id="CIT0002"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Akdis</surname>
<given-names>CA</given-names></string-name>, <string-name><surname>Arkwright</surname>
<given-names>PD</given-names></string-name>, <string-name><surname>Br&#x000fc;ggen</surname>
<given-names>MC</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Type 2 immunity in the skin and lungs</article-title>. <source>Allergy</source>. <year>2020</year>;<volume>75</volume>(<issue>7</issue>):<fpage>1582</fpage>&#x02013;<lpage>1605</lpage>. doi: <pub-id pub-id-type="doi">10.1111/all.14318</pub-id>.<pub-id pub-id-type="pmid">32319104</pub-id>
</mixed-citation></ref><ref id="CIT0003"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cavani</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Pennino</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Eyerich</surname>
<given-names>K.</given-names></string-name></person-group>
<article-title>Th17 and Th22 in skin allergy</article-title>. <source>Chem Immunol Allergy</source>. <year>2012</year>;<volume>96</volume>:<fpage>39</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">22433369</pub-id>
</mixed-citation></ref><ref id="CIT0004"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Didona</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Scarsella</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Fehresti</surname>
<given-names>M</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Autoreactive peripheral blood T helper cell responses in bullous pemphigoid and elderly patients with pruritic disorders</article-title>. <source>Front Immunol</source>. <year>2021</year>;<volume>12</volume>:<fpage>569287</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2021.569287</pub-id>.<pub-id pub-id-type="pmid">33841390</pub-id>
</mixed-citation></ref><ref id="CIT0005"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mukhatayev</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Ostapchuk</surname>
<given-names>YO</given-names></string-name>, <string-name><surname>Fang</surname>
<given-names>D</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Engineered antigen-specific regulatory T cells for autoimmune skin conditions</article-title>. <source>Autoimmun Rev</source>. <year>2021</year>;<volume>20</volume>(<issue>3</issue>):<fpage>102761</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.autrev.2021.102761</pub-id>.<pub-id pub-id-type="pmid">33476816</pub-id>
</mixed-citation></ref><ref id="CIT0006"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ahmed</surname>
<given-names>AR</given-names></string-name>, <string-name><surname>Anwar</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Reche</surname>
<given-names>PA.</given-names></string-name></person-group>
<article-title>Molecular basis for global incidence of pemphigoid diseases and differences in phenotypes</article-title>. <source>Front Immunol</source>. <year>2022</year>;<volume>13</volume>:<fpage>807173</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2022.807173</pub-id>.<pub-id pub-id-type="pmid">35126393</pub-id>
</mixed-citation></ref><ref id="CIT0007"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>B&#x000fc;dinger</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Borradori</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Yee</surname>
<given-names>C</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls</article-title>. <source>J Clin Invest</source>. <year>1998</year>;<volume>102</volume>(<issue>12</issue>):<fpage>2082</fpage>&#x02013;<lpage>2089</lpage>. doi: <pub-id pub-id-type="doi">10.1172/JCI3335</pub-id>.<pub-id pub-id-type="pmid">9854043</pub-id>
</mixed-citation></ref><ref id="CIT0008"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lin</surname>
<given-names>MS</given-names></string-name>, <string-name><surname>Fu</surname>
<given-names>CL</given-names></string-name>, <string-name><surname>Giudice</surname>
<given-names>GJ</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Epitopes targeted by bullous pemphigoid T lymphocytes and autoantibodies map to the same sites on the bullous pemphigoid 180 ectodomain</article-title>. <source>J Invest Dermatol</source>. <year>2000</year>;<volume>115</volume>(<issue>6</issue>):<fpage>955</fpage>&#x02013;<lpage>961</lpage>. doi: <pub-id pub-id-type="doi">10.1046/j.1523-1747.2000.00153.x</pub-id>.<pub-id pub-id-type="pmid">11121125</pub-id>
</mixed-citation></ref><ref id="CIT0009"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Watanabe</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Yamada</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Murakami</surname>
<given-names>H.</given-names></string-name></person-group>
<article-title>Expression of Th1/Th2 cell-related chemokine receptors on CD4(+) lymphocytes under physiological conditions</article-title>. <source>Int J Lab Hematol</source>. <year>2020</year>;<volume>42</volume>(<issue>1</issue>):<fpage>68</fpage>&#x02013;<lpage>76</lpage>. doi: <pub-id pub-id-type="doi">10.1111/ijlh.13141</pub-id>.</mixed-citation></ref><ref id="CIT0010"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tanita</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Fujimura</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Sato</surname>
<given-names>Y</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Minocycline decreases Th2 chemokines from M2 macrophages: possible mechanisms for the suppression of bullous pemphigoid by traditional bullous disease drugs</article-title>. <source>Exp Dermatol</source>. <year>2018</year>;<volume>27</volume>(<issue>11</issue>):<fpage>1268</fpage>&#x02013;<lpage>1272</lpage>. doi: <pub-id pub-id-type="doi">10.1111/exd.13779</pub-id>.<pub-id pub-id-type="pmid">30192415</pub-id>
</mixed-citation></ref><ref id="CIT0011"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nakashima</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Fujimoto</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Asashima</surname>
<given-names>N</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Serum chemokine profile in patients with bullous pemphigoid</article-title>. <source>Br J Dermatol</source>. <year>2007</year>;<volume>156</volume>(<issue>3</issue>):<fpage>454</fpage>&#x02013;<lpage>459</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1365-2133.2006.07601.x</pub-id>.<pub-id pub-id-type="pmid">17300233</pub-id>
</mixed-citation></ref><ref id="CIT0012"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Eming</surname>
<given-names>R</given-names></string-name>, <string-name><surname>B&#x000fc;dinger</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Riechers</surname>
<given-names>R</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Frequency analysis of autoreactive T-helper 1 and 2 cells in bullous pemphigoid and pemphigus vulgaris by enzyme-linked immunospot assay</article-title>. <source>Br J Dermatol</source>. <year>2000</year>;<volume>143</volume>(<issue>6</issue>):<fpage>1279</fpage>&#x02013;<lpage>1282</lpage>. doi: <pub-id pub-id-type="doi">10.1046/j.1365-2133.2000.03901.x</pub-id>.<pub-id pub-id-type="pmid">11122034</pub-id>
</mixed-citation></ref><ref id="CIT0013"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>De Bruyn Carlier</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Badloe</surname>
<given-names>FMS</given-names></string-name>, <string-name><surname>Ring</surname>
<given-names>J</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Autoreactive T cells and their role in atopic dermatitis</article-title>. <source>J Autoimmun</source>. <year>2021</year>;<volume>120</volume>:<fpage>102634</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jaut.2021.102634</pub-id>.<pub-id pub-id-type="pmid">33892348</pub-id>
</mixed-citation></ref><ref id="CIT0014"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kridin</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Hammers</surname>
<given-names>CM</given-names></string-name>, <string-name><surname>Ludwig</surname>
<given-names>RJ</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>The association of bullous pemphigoid with atopic dermatitis and allergic rhinitis&#x02014;a population-based study</article-title>. <source>Dermatitis</source>. <year>2022</year>;<volume>33</volume>(<issue>4</issue>):<fpage>268</fpage>&#x02013;<lpage>276</lpage>. doi: <pub-id pub-id-type="doi">10.1097/DER.0000000000000792</pub-id>.<pub-id pub-id-type="pmid">34570736</pub-id>
</mixed-citation></ref><ref id="CIT0015"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tabatabaei-Panah</surname>
<given-names>PS</given-names></string-name>, <string-name><surname>Moravvej</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Alirajab</surname>
<given-names>M</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Association between TH2 cytokine gene polymorphisms and risk of bullous pemphigoid</article-title>. <source>Immunol Invest</source>. <year>2022</year>;<volume>51</volume>(<issue>2</issue>):<fpage>343</fpage>&#x02013;<lpage>356</lpage>. doi: <pub-id pub-id-type="doi">10.1080/08820139.2020.1832113</pub-id>.<pub-id pub-id-type="pmid">33047635</pub-id>
</mixed-citation></ref><ref id="CIT0016"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shen</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Yuan</surname>
<given-names>HJ</given-names></string-name>, <string-name><surname>Pan</surname>
<given-names>M.</given-names></string-name></person-group>
<article-title>The role of eosinophils in the pathogenesis of bullous pemphigoid</article-title>. <source>Chin J Dermatol</source>. <year>2019</year>;<volume>52</volume>(<issue>8</issue>):<fpage>579</fpage>&#x02013;<lpage>581</lpage>.</mixed-citation></ref><ref id="CIT0017"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jones</surname>
<given-names>VA</given-names></string-name>, <string-name><surname>Patel</surname>
<given-names>PM</given-names></string-name>, <string-name><surname>Amber</surname>
<given-names>KT.</given-names></string-name></person-group>
<article-title>Eosinophils in bullous pemphigoid</article-title>. <source>Panminerva Med</source>. <year>2021</year>;<volume>63</volume>(<issue>3</issue>):<fpage>368</fpage>&#x02013;<lpage>378</lpage>. doi: <pub-id pub-id-type="doi">10.23736/S0031-0808.20.03997-X</pub-id>.<pub-id pub-id-type="pmid">32536149</pub-id>
</mixed-citation></ref><ref id="CIT0018"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Russo</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Cozzani</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Gasparini</surname>
<given-names>G</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Targeting interleukin 4 receptor &#x003b1;: a new approach to the treatment of cutaneous autoimmune bullous diseases?</article-title>
<source>Dermatol Ther</source>. <year>2020</year>;<volume>33</volume>(<issue>1</issue>):<fpage>e13190</fpage>.<pub-id pub-id-type="pmid">31863534</pub-id>
</mixed-citation></ref><ref id="CIT0019"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>G&#x000fc;nther</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Carballido-Perrig</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Kopp</surname>
<given-names>T</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>CCL18 is expressed in patients with bullous pemphigoid and parallels disease course</article-title>. <source>Br J Dermatol</source>. <year>2009</year>;<volume>160</volume>(<issue>4</issue>):<fpage>747</fpage>&#x02013;<lpage>755</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1365-2133.2008.08979.x</pub-id>.<pub-id pub-id-type="pmid">19120345</pub-id>
</mixed-citation></ref><ref id="CIT0020"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Karo-Atar</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Bitton</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Benhar</surname>
<given-names>I</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Therapeutic targeting of the interleukin-4/interleukin-13 signaling pathway: in allergy and beyond</article-title>. <source>BioDrugs</source>. <year>2018</year>;<volume>32</volume>(<issue>3</issue>):<fpage>201</fpage>&#x02013;<lpage>220</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40259-018-0280-7</pub-id>.<pub-id pub-id-type="pmid">29736903</pub-id>
</mixed-citation></ref><ref id="CIT0021"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pickford</surname>
<given-names>WJ</given-names></string-name>, <string-name><surname>Gudi</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Haggart</surname>
<given-names>AM</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>T cell participation in autoreactivity to NC16a epitopes in bullous pemphigoid</article-title>. <source>Clin Exp Immunol</source>. <year>2015</year>;<volume>180</volume>(<issue>2</issue>):<fpage>189</fpage>&#x02013;<lpage>200</lpage>. doi: <pub-id pub-id-type="doi">10.1111/cei.12566</pub-id>.<pub-id pub-id-type="pmid">25472480</pub-id>
</mixed-citation></ref><ref id="CIT0022"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Fang</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Shen</surname>
<given-names>S</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Identification of immunodominant Th2-cell epitopes in Chinese patients with bullous pemphigoid</article-title>. <source>J Invest Dermatol</source>. <year>2018</year>;<volume>138</volume>(<issue>9</issue>):<fpage>1917</fpage>&#x02013;<lpage>1924</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jid.2018.03.1515</pub-id>.<pub-id pub-id-type="pmid">29588155</pub-id>
</mixed-citation></ref><ref id="CIT0023"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gounni Abdelilah</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Wellemans</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Agouli</surname>
<given-names>M</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Increased expression of Th2-associated chemokines in bullous pemphigoid disease. Role of eosinophils in the production and release of these chemokines</article-title>. <source>Clin Immunol</source>. <year>2006</year>;<volume>120</volume>(<issue>2</issue>):<fpage>220</fpage>&#x02013;<lpage>231</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.clim.2006.03.014</pub-id>.<pub-id pub-id-type="pmid">16782408</pub-id>
</mixed-citation></ref><ref id="CIT0024"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Afarideh</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Borucki</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Werth</surname>
<given-names>VP.</given-names></string-name></person-group>
<article-title>A review of the immunologic pathways involved in bullous pemphigoid and novel therapeutic targets</article-title>. <source>J Clin Med</source>. <year>2022</year>;<volume>11</volume>(<issue>10</issue>):<fpage>2856</fpage>. doi: <pub-id pub-id-type="doi">10.3390/jcm11102856</pub-id>.<pub-id pub-id-type="pmid">35628982</pub-id>
</mixed-citation></ref><ref id="CIT0025"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cirillo</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Prime</surname>
<given-names>SS.</given-names></string-name></person-group>
<article-title>A scoping review of the role of metalloproteinases in the pathogenesis of autoimmune pemphigus and pemphigoid</article-title>. <source>Biomolecules</source>. <year>2021</year>;<volume>11</volume>(<issue>10</issue>):<fpage>1506</fpage>. doi: <pub-id pub-id-type="doi">10.3390/biom11101506</pub-id>.<pub-id pub-id-type="pmid">34680139</pub-id>
</mixed-citation></ref><ref id="CIT0026"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kowalski</surname>
<given-names>EH</given-names></string-name>, <string-name><surname>Kneibner</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Kridin</surname>
<given-names>K</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Serum and blister fluid levels of cytokines and chemokines in pemphigus and bullous pemphigoid</article-title>. <source>Autoimmun Rev</source>. <year>2019</year>;<volume>18</volume>(<issue>5</issue>):<fpage>526</fpage>&#x02013;<lpage>534</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.autrev.2019.03.009</pub-id>.<pub-id pub-id-type="pmid">30844553</pub-id>
</mixed-citation></ref><ref id="CIT0027"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kabuto</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Fujimoto</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Takahashi</surname>
<given-names>T</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Decreased level of interleukin-10-producing B cells in patients with pemphigus but not in patients with pemphigoid</article-title>. <source>Br J Dermatol</source>. <year>2017</year>;<volume>176</volume>(<issue>5</issue>):<fpage>1204</fpage>&#x02013;<lpage>1212</lpage>. doi: <pub-id pub-id-type="doi">10.1111/bjd.15113</pub-id>.<pub-id pub-id-type="pmid">27716906</pub-id>
</mixed-citation></ref><ref id="CIT0028"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Antiga</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Quaglino</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Volpi</surname>
<given-names>W</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Regulatory T cells in skin lesions and blood of patients with bullous pemphigoid</article-title>. <source>J Eur Acad Dermatol Venereol</source>. <year>2014</year>;<volume>28</volume>(<issue>2</issue>):<fpage>222</fpage>&#x02013;<lpage>230</lpage>. doi: <pub-id pub-id-type="doi">10.1111/jdv.12091</pub-id>.<pub-id pub-id-type="pmid">23331964</pub-id>
</mixed-citation></ref><ref id="CIT0029"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Dang</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>B</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Dysfunction of CD19(+)CD24(hi)CD27(+) B regulatory cells in patients with bullous pemphigoid</article-title>. <source>Sci Rep</source>. <year>2018</year>;<volume>8</volume>(<issue>1</issue>):<fpage>703</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-018-19226-z</pub-id>.<pub-id pub-id-type="pmid">29335495</pub-id>
</mixed-citation></ref><ref id="CIT0030"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Riani</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Muller</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Bour</surname>
<given-names>C</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Blister fluid induces MMP-9-associated M2-type macrophages in bullous pemphigoid</article-title>. <source>Front Immunol</source>. <year>2019</year>;<volume>10</volume>:<fpage>1858</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2019.01858</pub-id>.<pub-id pub-id-type="pmid">31440247</pub-id>
</mixed-citation></ref><ref id="CIT0031"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Berkani</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Joly</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Golinski</surname>
<given-names>ML</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>B-cell depletion induces a shift in self antigen specific B-cell repertoire and cytokine pattern in patients with bullous pemphigoid</article-title>. <source>Sci Rep</source>. <year>2019</year>;<volume>9</volume>(<issue>1</issue>):<fpage>3525</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-019-40203-7</pub-id>.<pub-id pub-id-type="pmid">30837635</pub-id>
</mixed-citation></ref><ref id="CIT0032"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Mao</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>Y</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>IL-13 genetic susceptibility to bullous pemphigoid: a potential target for treatment and a prognostic marker</article-title>. <source>Front Immunol</source>. <year>2022</year>;<volume>13</volume>:<fpage>824110</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2022.824110</pub-id>.<pub-id pub-id-type="pmid">35140724</pub-id>
</mixed-citation></ref><ref id="CIT0033"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bridgewood</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Sharif</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Freeston</surname>
<given-names>J</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Regulation of entheseal IL-23 expression by IL-4 and IL-13 as an explanation for arthropathy development under dupilumab therapy</article-title>. <source>Rheumatology</source>. <year>2021</year>;<volume>60</volume>(<issue>5</issue>):<fpage>2461</fpage>&#x02013;<lpage>2466</lpage>. doi: <pub-id pub-id-type="doi">10.1093/rheumatology/keaa568</pub-id>.<pub-id pub-id-type="pmid">33253386</pub-id>
</mixed-citation></ref><ref id="CIT0034"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhou</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Peng</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Geng</surname>
<given-names>S.</given-names></string-name></person-group>
<article-title>Emerging biomarkers and therapeutic strategies for refractory bullous pemphigoid</article-title>. <source>Front Immunol</source>. <year>2021</year>;<volume>12</volume>:<fpage>718073</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2021.718073</pub-id>.<pub-id pub-id-type="pmid">34504496</pub-id>
</mixed-citation></ref><ref id="CIT0035"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cozzani</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Gasparini</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Di Zenzo</surname>
<given-names>G</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Immunoglobulin E and bullous pemphigoid</article-title>. <source>Eur J Dermatol</source>. <year>2018</year>;<volume>28</volume>(<issue>4</issue>):<fpage>440</fpage>&#x02013;<lpage>448</lpage>. doi: <pub-id pub-id-type="doi">10.1684/ejd.2018.3366</pub-id>.<pub-id pub-id-type="pmid">30325326</pub-id>
</mixed-citation></ref><ref id="CIT0036"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xiong</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Dolpady</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Wabl</surname>
<given-names>M</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Sequential class switching is required for the generation of high affinity IgE antibodies</article-title>. <source>J Exp Med</source>. <year>2012</year>;<volume>209</volume>(<issue>2</issue>):<fpage>353</fpage>&#x02013;<lpage>364</lpage>. doi: <pub-id pub-id-type="doi">10.1084/jem.20111941</pub-id>.<pub-id pub-id-type="pmid">22249450</pub-id>
</mixed-citation></ref><ref id="CIT0037"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Boehncke</surname>
<given-names>WH</given-names></string-name>, <string-name><surname>Brembilla</surname>
<given-names>NC.</given-names></string-name></person-group>
<article-title>Autoreactive T-lymphocytes in inflammatory skin diseases</article-title>. <source>Front Immunol</source>. <year>2019</year>;<volume>10</volume>:<fpage>1198</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2019.01198</pub-id>.<pub-id pub-id-type="pmid">31191553</pub-id>
</mixed-citation></ref><ref id="CIT0038"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bao</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Solimani</surname>
<given-names>F</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Subunit-specific reactivity of autoantibodies against laminin-332 reveals direct inflammatory mechanisms on keratinocytes</article-title>. <source>Front Immunol</source>. <year>2021</year>;<volume>12</volume>:<fpage>775412</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2021.775412</pub-id>.<pub-id pub-id-type="pmid">34899732</pub-id>
</mixed-citation></ref><ref id="CIT0039"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kridin</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Ludwig</surname>
<given-names>RJ</given-names></string-name>, <string-name><surname>Tzur Bitan</surname>
<given-names>D</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>A history of asthma increases the risk of bullous pemphigoid: insights from a large population-based study</article-title>. <source>Dermatology</source>. <year>2021</year>;<volume>237</volume>(<issue>6</issue>):<fpage>921</fpage>&#x02013;<lpage>928</lpage>. doi: <pub-id pub-id-type="doi">10.1159/000512917</pub-id>.<pub-id pub-id-type="pmid">33640889</pub-id>
</mixed-citation></ref><ref id="CIT0040"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tabatabaei-Panah</surname>
<given-names>PS</given-names></string-name>, <string-name><surname>Moravvej</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Aghaei</surname>
<given-names>S</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>TH17/IL23 cytokine gene polymorphisms in bullous pemphigoid</article-title>. <source>Mol Genet Genomic Med</source>. <year>2020</year>;<volume>8</volume>(<issue>12</issue>):<fpage>e1519</fpage>.<pub-id pub-id-type="pmid">33340282</pub-id>
</mixed-citation></ref><ref id="CIT0041"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hsieh</surname>
<given-names>CY</given-names></string-name>, <string-name><surname>Tsai</surname>
<given-names>TF.</given-names></string-name></person-group>
<article-title>Management of coexisting bullous pemphigoid and psoriasis: a review</article-title>. <source>Am J Clin Dermatol</source>. <year>2022</year>;<volume>23</volume>(<issue>6</issue>):<fpage>869</fpage>&#x02013;<lpage>879</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40257-022-00719-7</pub-id>.<pub-id pub-id-type="pmid">35964277</pub-id>
</mixed-citation></ref><ref id="CIT0042"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Giusti</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Bini</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Terryn</surname>
<given-names>C</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>NET formation in bullous pemphigoid patients with relapse is modulated by IL-17 and IL-23 interplay</article-title>. <source>Front Immunol</source>. <year>2019</year>;<volume>10</volume>:<fpage>701</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2019.00701</pub-id>.<pub-id pub-id-type="pmid">31019514</pub-id>
</mixed-citation></ref><ref id="CIT0043"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chakievska</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Holtsche</surname>
<given-names>MM</given-names></string-name>, <string-name><surname>K&#x000fc;nstner</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid</article-title>. <source>J Autoimmun</source>. <year>2019</year>;<volume>96</volume>:<fpage>104</fpage>&#x02013;<lpage>112</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jaut.2018.09.003</pub-id>.<pub-id pub-id-type="pmid">30219389</pub-id>
</mixed-citation></ref><ref id="CIT0044"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pl&#x000e9;e</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Le Jan</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Giustiniani</surname>
<given-names>J</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Integrating longitudinal serum IL-17 and IL-23 follow-up, along with autoantibodies variation, contributes to predict bullous pemphigoid outcome</article-title>. <source>Sci Rep</source>. <year>2015</year>;<volume>5</volume>(<issue>1</issue>):<fpage>18001</fpage>. doi: <pub-id pub-id-type="doi">10.1038/srep18001</pub-id>.<pub-id pub-id-type="pmid">26656739</pub-id>
</mixed-citation></ref><ref id="CIT0045"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Leijs</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Fietkau</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Merk</surname>
<given-names>HF</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Upregulation of CCL7, CCL20, CXCL2, IL-1&#x003b2;, IL-6 and MMP-9 in skin samples of PCB exposed individuals&#x02014;a preliminary study</article-title>. <source>Int J Environ Res Public Health</source>. <year>2021</year>;<volume>18</volume>(<issue>18</issue>):<fpage>9711</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijerph18189711</pub-id>.<pub-id pub-id-type="pmid">34574641</pub-id>
</mixed-citation></ref><ref id="CIT0046"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>De Graauw</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Sitaru</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Horn</surname>
<given-names>M</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Evidence for a role of eosinophils in blister formation in bullous pemphigoid</article-title>. <source>Allergy</source>. <year>2017</year>;<volume>72</volume>(<issue>7</issue>):<fpage>1105</fpage>&#x02013;<lpage>1113</lpage>. doi: <pub-id pub-id-type="doi">10.1111/all.13131</pub-id>.<pub-id pub-id-type="pmid">28135772</pub-id>
</mixed-citation></ref><ref id="CIT0047"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Britt</surname>
<given-names>RD</given-names></string-name>, <string-name><surname>Thompson</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>Sasse</surname>
<given-names>S</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Th1 cytokines TNF-&#x003b1; and IFN-&#x003b3; promote corticosteroid resistance in developing human airway smooth muscle</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source>. <year>2019</year>;<volume>316</volume>(<issue>1</issue>):<fpage>L71</fpage>&#x02013;<lpage>L81</lpage>. doi: <pub-id pub-id-type="doi">10.1152/ajplung.00547.2017</pub-id>.<pub-id pub-id-type="pmid">30335498</pub-id>
</mixed-citation></ref><ref id="CIT0048"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>Y</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>E4BP4 facilitates glucocorticoid sensitivity of human bronchial epithelial cells via down-regulation of glucocorticoid receptor-beta</article-title>. <source>Cell Immunol</source>. <year>2018</year>;<volume>334</volume>:<fpage>31</fpage>&#x02013;<lpage>37</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cellimm.2018.08.015</pub-id>.<pub-id pub-id-type="pmid">30153899</pub-id>
</mixed-citation></ref><ref id="CIT0049"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vazquez-Tello</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Halwani</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Hamid</surname>
<given-names>Q</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Glucocorticoid receptor-beta up-regulation and steroid resistance induction by IL-17 and IL-23 cytokine stimulation in peripheral mononuclear cells</article-title>. <source>J Clin Immunol</source>. <year>2013</year>;<volume>33</volume>(<issue>2</issue>):<fpage>466</fpage>&#x02013;<lpage>478</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10875-012-9828-3</pub-id>.<pub-id pub-id-type="pmid">23160983</pub-id>
</mixed-citation></ref><ref id="CIT0050"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cao</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Xu</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>L.</given-names></string-name></person-group>
<article-title>Rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid: a systematic review</article-title>. <source>Front Immunol</source>. <year>2022</year>;<volume>13</volume>:<fpage>928621</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2022.928621</pub-id>.<pub-id pub-id-type="pmid">35769474</pub-id>
</mixed-citation></ref><ref id="CIT0051"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Simon</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Yousefi</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Cazzaniga</surname>
<given-names>S</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Mepolizumab failed to affect bullous pemphigoid: a randomized, placebo-controlled, double-blind phase 2 pilot study</article-title>. <source>Allergy</source>. <year>2020</year>;<volume>75</volume>(<issue>3</issue>):<fpage>669</fpage>&#x02013;<lpage>672</lpage>. doi: <pub-id pub-id-type="doi">10.1111/all.13950</pub-id>.<pub-id pub-id-type="pmid">31230371</pub-id>
</mixed-citation></ref></ref-list></back></article>
